Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients planned to undergo osteosynthesis with short intramedullary nail for a pertrochanteric hip fracture.~* ASA score 3, 2 or 1~Exclusion Criteria:~* Allergy for tranexamic acid~* Clinical signs of acute thromboembolic event~* Renal function impairment (S-creatinin\>120micromol/l)~* Active thrombotic disease or DIC~* K-vitamin antagonist treatment~* Malignancy~* Pathological fracture~* Previously operated in same hip~* BW \> 100kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Patients are given saline instead of tranexamic acid in the placebo group
- Tranexamic Acid (Type: ACTIVE_COMPARATOR): Tranexamic acid; 1 gram as a bolus prior to surgery. 3 grams of Tranexamic acid in 1 liter of saline as a 24 hour infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).